CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model

BACKGROUND: CD47/SIRPα axis is recognized as an innate immune checkpoint and emerging clinical data validate the interest of interrupting this pathway in cancer, particularly in hematological malignancies. In preclinical models, CD47/SIRPα blocking agents have been shown to mobilize phagocytic cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauchet, Xavier, Cons, Laura, Chatel, Laurence, Daubeuf, Bruno, Didelot, Gérard, Moine, Valéry, Chollet, Didier, Malinge, Pauline, Pontini, Guillemette, Masternak, Krzysztof, Ferlin, Walter, Buatois, Vanessa, Shang, Limin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088114/
https://www.ncbi.nlm.nih.gov/pubmed/35538512
http://dx.doi.org/10.1186/s40164-022-00279-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088114/
https://www.ncbi.nlm.nih.gov/pubmed/35538512
http://dx.doi.org/10.1186/s40164-022-00279-w

Ejemplares similares